Donnatal is expensive because a single company controls its production, no FDA-approved generic exists, and the drug occupies a regulatory gray area that shields it from the normal competition that drives prices down. A 100-tablet supply currently runs about $1,436, or roughly $14.36 per tablet, making it one of the priciest options for a condition with far cheaper treatments available.
A Drug That Predates Modern FDA Approval
Donnatal is a combination of four ingredients: phenobarbital (a mild sedative), plus three belladonna alkaloids that slow gut spasms. It has been on the market since before 1962, the year Congress required drugmakers to prove their products actually work, not just that they’re safe. Drugs already on the market at that time were supposed to go through a review process called the Drug Efficacy Study Implementation, or DESI, to confirm they were effective.
Donnatal’s DESI review was never completed. Its case file, opened in the 1970s, remains open to this day. That means the FDA has never formally determined that Donnatal works for the conditions it’s prescribed for. The drug stays on the market because the FDA’s policy allows products with unresolved DESI proceedings to continue being sold while the review is pending. It has been pending for roughly 50 years.
This matters for pricing because the unresolved status creates an unusual situation. Donnatal is not technically an FDA-approved drug, which means generic manufacturers can’t use the standard pathway to bring a cheaper copy to market. At the same time, it’s not unapproved enough to be pulled from pharmacies. The result is a product with no real regulatory competition.
One Manufacturer, No Generic Competition
In 2014, Concordia Healthcare (now Advanz Pharma) acquired the rights to Donnatal for $200 million in cash plus company stock. After completing that acquisition, the company implemented what it called “cost adjustments based on market assessments,” a corporate phrase for significant price increases. This was part of a broader business model focused on buying older drugs with limited competition and raising their prices.
Because no FDA-approved generic version of Donnatal exists, there’s nothing to keep the price in check. In most drug markets, generics enter after patents expire and drive costs down by 80% or more. Donnatal’s unusual DESI status means it never went through the approval process that would create a clear pathway for generic entry. Some pharmacies carry unapproved versions of the same ingredient combination, but these aren’t formally reviewed by the FDA either, and their availability is inconsistent.
Insurance Plans Often Won’t Cover It
The price hits patients especially hard because many insurance plans, including Medicare Part D, exclude Donnatal from coverage. Medicare specifically excludes two categories that apply here: drugs classified as “less-than-effective” DESI products and barbiturates. Donnatal falls into both. Many private insurers follow similar guidelines.
That leaves patients paying the full cash price out of pocket, which at over $1,400 for a 100-tablet supply can be a serious financial burden, particularly for a medication taken multiple times daily. Even with discount programs, the cost remains far higher than comparable alternatives.
Cheaper Alternatives Exist
Donnatal is typically prescribed for irritable bowel syndrome and similar gut conditions, but it’s not a first-line treatment by modern standards. Drugs like dicyclomine and hyoscyamine target gut spasms through similar mechanisms, are FDA-approved, widely available as generics, and cost a fraction of Donnatal’s price. A month’s supply of generic dicyclomine often runs under $20.
The clinical case for Donnatal over these alternatives is weak. A randomized, double-blind trial found that adding Donnatal to an antacid did not relieve digestive symptoms any better than the antacid alone. No large modern studies support Donnatal as superior to cheaper antispasmodic options. The drug persists largely because of physician habit and patient familiarity rather than evidence of unique effectiveness.
Why the Price Stays High
Donnatal’s cost is the product of several reinforcing factors working together. The unresolved DESI status blocks generic competition. A single company controls production and sets prices without market pressure. Insurance exclusions mean there’s no large payer pushing back on costs. And the FDA has shown no urgency to resolve a regulatory proceeding that has sat open since the 1970s.
If your doctor has prescribed Donnatal and the cost is a barrier, it’s worth asking whether a generic antispasmodic like dicyclomine or hyoscyamine could work for your symptoms. For most patients with IBS or gut cramping, these alternatives offer similar relief at a small fraction of the price and carry the added reassurance of full FDA approval.